A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Other Indications, Blood Cancer, Lymphoma, Hematology |
| Therapuetic Areas: | Hematology, Oncology, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2009 |
| End Date: | March 2012 |
The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in
subjects with advanced hematological malignancies, and to further assess the safety and
tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to
select a dose for future studies.
We found this trial at
1
site
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health Systems The University of Michigan is home to one of the...
Click here to add this to my saved trials
